Drug
Acoramidis clinical trials
Also written AG10 and ALXN2060.
- studies test it
- 15
- open now
- 5
- in phase 3
- 7
- first study started
- 2017
Keep track of what changes. Save the acoramidis studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- AG10
- 10
Studies by the year they started
15 studies that test it; most in 2021 (4)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 4 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 2
- Phase 3
- 7
- Phase 4
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 0
Eidos Therapeutics, a BridgeBio company (11) · Alexion Pharmaceuticals, Inc. (3) · Bayer (1)
Studies
Open first, then newest update. How each study uses acoramidis is read from its arms, and is right about nine times in ten.
Testing it · 15
- A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to AcoramidisRecruitingPhase 4BayerNCT07298044Written as Acoramidis
- To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)Not yet recruitingPhase 3Eidos Therapeutics, a BridgeBio companyNCT07116473Written as Acoramidis (AG10)
- Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantRecruitingPhase 3Eidos Therapeutics, a BridgeBio companyNCT06563895Written as Acoramidis
- Cardiac Magnetic Resonance and Echocardiography Study With AcoramidisRecruitingPhase 4Eidos Therapeutics, a BridgeBio companyNCT07695701Written as Acoramidis (AG10) oral tablet
- Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac BiomarkersRecruitingPhase 4Alexion Pharmaceuticals, Inc.NCT07306949Written as Acoramidis
- Open-Label Study of AG10 in Patients With CardiomyopathyTerminatedPhase 2Eidos Therapeutics, a BridgeBio companyNCT03536767Written as Acoramidis
- A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CMCompletedPhase 3Alexion Pharmaceuticals, Inc.NCT04622046Written as ALXN2060
- Study to Assess the Effect of Food on a Single Dose of Acoramidis in Healthy Adult ParticipantsCompletedPhase 1Alexion Pharmaceuticals, Inc.NCT04958135Written as Acoramidis
- Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR ParticipantsActive, not recruitingPhase 3Eidos Therapeutics, a BridgeBio companyNCT04988386Written as Acoramidis (AG10)
- A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy SubjectsCompletedPhase 1Eidos Therapeutics, a BridgeBio companyNCT04769479Written as acoramidis
- Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10CompletedPhase 1Eidos Therapeutics, a BridgeBio companyNCT03294707Written as AG10 oral tablet
- Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)WithdrawnPhase 3Eidos Therapeutics, a BridgeBio companyNCT04882735Written as Acoramidis
- Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid PolyneurophathyWithdrawnPhase 3Eidos Therapeutics, a BridgeBio companyNCT04418024Written as AG10
- Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid CardiomyopathyCompletedPhase 3Eidos Therapeutics, a BridgeBio companyNCT03860935Written as acoramidis
- Study of AG10 in Amyloid CardiomyopathyCompletedPhase 2Eidos Therapeutics, a BridgeBio companyNCT03458130Written as AG10
Codes
What other systems call acoramidis · ClinicalTrials.gg INT002107
- MeSH (NLM) C000731204acoramidisConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) T12B44A1OEACORAMIDISConfirmed FDA, NLM, Wikidata
- Wikidata Q27451739acoramidisConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C170791AcoramidisOne source FDA
- DrugBank DB17999One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731204 | acoramidis | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | T12B44A1OE | ACORAMIDIS | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27451739 | acoramidis | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C170791 | Acoramidis | One source FDA |
| DrugBank | DB17999 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.